March 25, 2024
Takeda Pharmaceutical’s cancer drug Iclusig (ponatinib) has bagged accelerated approval from the US FDA for its label expansion into the frontline treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The drug gained the thumbs-up on March 19 to treat...read more